Category Archives: Investment

Senators seek probe of Allergan’s patent sale to Mohawk Tribe; could Tesla do the same with its battery patents?

The News: Four senators are demanding an investigation of Allergan PLC’s (Dublin IRL) first-of-a-kind patent deal with the Saint Regis Mohawk Tribe, alleging the move to protect Restasis is another… Read more »

Alnylam soars on RNAi success as Phase 3 patisiran study hits all goals; market overreacts as pipeline unproven and competition lurks.

The News: Alnylam Pharmaceuticals Inc.’s (Cambridge MA) RNAi-based drug that targets a rare genetic disease cleared a key study, in a breakthrough for the new class of medicines that works… Read more »

Zai Lab’s U.S. IPO marks another white-hot Chinese offering that begs the question: why are these Asian offerings so special?

The News: Shang­hai-based biotech Zai Lab Ltd. raised $150 mil­lion from its up­sized IPO last Wednes­day (September 20, 2017), sell­ing 8.3 mil­lion shares at $18 each. After trad­ing began, the… Read more »

Weekly stock roundup: Marinus, McKesson are Buys, but not for everyone.

Marinus Pharmaceuticals Inc. (Nasdaq:MRNS) was among the top advancing issues last week, soaring 31% to $4.10. Investors pounced on shares after the Radnor, PA-based drugmaker announced that top-line data from… Read more »

Slumbering giant Lilly to cut more jobs, take a $1.2-billion hit to bolster R&D pipeline.

The News: Eli Lilly & Co. (Indianapolis IN) last week said it would lay off about 8% of its employees as the drugmaker, which has suffered setbacks over the past… Read more »

Stock round-up features superb week for Insmed and NewLink; not so much for Cellectis.

Insmed Inc. (Nasdaq:INSM) led advancing issues, more than doubling (+146%) over the week, to $30.25 as of Tuesday morning, September 12. The explosion began after the company announced that its… Read more »

Health stocks soar going into Labor Day weekend; well, not everyone. Here’s my take on three big movers: Abeona, UroGen and Otonomy.

Abeona Therapeutics Inc. (Nasdaq:ABEO) led advancing issues, soaring 57% over the week to $14.20 as of close Tuesday, Sept. 5. That huge gain resulted primarily from the US Food and… Read more »

Intra-Cellular shares zoom higher; is buying this name a gamble or a rational bet?

The News: Intra-Cellular Therapies Inc. (Nasdaq:ITCI) rocketed 41% over the past week to $15.70 on a positive regulatory update from the US Food and Drug Administration regarding its lumateperone treatment for schizophrenia…. Read more »

Winners outpace losers in wild week for healthcare stocks; my picks and pans.

Leading the largest pack of winners in quite a while, XOMA Corp. (Nasdaq:XOMA) soared $5.64, or 48% over the week, to $11.10, after the company revealed an agreement to out-license… Read more »

Alexion on a roll as Soliris gets label expansion in EU; although flying under the radar, analysts, investors still bullish.

The News: Alexion Pharmaceuticals Inc. (New Haven CT) got another shot in the arm this week with the EU approving its key revenue driver Soliris for an additional indication. EU approval… Read more »